Obermatt
See Similar Stocks →

Precision BioSciences

NAQ:DTIL · US74019P2074
BiotechnologySmall

360

39
Profit price77
Owner Earnings Yield1
Dividend Yield1
Price/Sales59
EV / Gross Profit79
Price/Book18
Return on Capital71
Cash Return on Capital71
Return on Equity45
EBIT Margin30
Gross Profitability78
Accruals22
Owner Earnings Margin73
Sales growth26
Profit growth84
Reinvestment75
Price momentum45
Debt load21
Refinancing95
Debt Payback1
Liquidity53
Analyst ratings100
Expectations trend50
Market mood29
Value Creation10/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Precision BioSciences clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQCM
Founded2006
Employees93
Websiteprecisionbiosciences.com
ISINUS74019P2074
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Infectious DiseasesImmunologyCentral Nervous SystemGenetic DisorderOncologyGeneticsHepatologyBiotechnologyHealth CareMedical

Description

Precision BioSciences, Inc., a clinical stage gene editing company, utilizes its novel proprietary ARCUS platform to develop in vivo gene editing therapies. ARCUS differs from other technologies in the way it cuts, its smaller size, and its simpler…

Analysis

Middle-of-the-road

Precision BioSciences, Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is stretched. The company scores 10/20 on our value-creation score: creating some value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
58
2026

All-time high

58

Jun 2026

All-time low

30

Mar 2026

Average rank

44

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
59
—
—
—
Price/Earnings
42
—
—
—
Price/Book
18
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
8
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Precision BioSciences with its peers
Assembly Biosciences
NSQ:ASMB
33
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Gilead
NSQ:GILD
67
CountryUSA
IndustryBiotechnology
SizeXX-Large
Full Stock Analysis →
Replimune Group
NSQ:REPL
1
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Atea Pharmaceuticals
NSQ:AVIR
5
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Vir Biotechnology
NSQ:VIR
56
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Caribou Biosciences
NSQ:CRBU
39
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →